Gilead Sciences Prepares Global Innovation Showcase for Ninth CIIE

Gilead Sciences highlighted expanding opportunities stemming from China expanding high-level opening-up and encouraging pharmaceutical innovation ahead of the ninth China International Import Expo, according to China News Service. Jin Fangqian, global vice president and China general manager of Gilead Sciences, stated that the biopharmaceutical enterprise has attended the expo across multiple years. At the ninth edition of the expo, Gilead Sciences plans to showcase worldwide innovations covering oncology, antifungal conditions, liver disease, and pre-exposure prophylaxis for HIV within a 500 square meter booth. The display will also feature progress in moving multiple therapies into clinical use. The drugmaker plans to highlight lenacapavir, a long-acting HIV capsid inhibitor used for pre-exposure prophylaxis, alongside seladelpar, an innovative therapy designed for primary biliary cholangitis. Seladelpar gained approval under programs in Hainan Boao Lecheng and Beijing Tianzhu, while also entering several regional commercial health insurance foreign drug lists. Jin stated that the enterprise expects to maintain roots in China while deepening collaboration alongside the government, medical institutions, industry groups, and patient organizations. These partnerships aim to deliver global innovations to patients in China earlier and faster through ongoing local practices.